EVFM (Evofem Biosciences) Cyclically Adjusted PB Ratio: (As of Sep. 22, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Evofem Biosciences Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Evofem Biosciences  (OTCPK:EVFM) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Evofem Biosciences Cyclically Adjusted PB Ratio Related Terms


Evofem Biosciences Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Evofem Biosciences's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Evofem Biosciences Cyclically Adjusted PB Ratio Chart

Evofem Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Evofem Biosciences Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

EVFM vs BZYR, ZVSA, RMTG: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, Evofem Biosciences's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Evofem Biosciences Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Evofem Biosciences's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Evofem Biosciences's Cyclically Adjusted PB Ratio falls into.



Evofem Biosciences Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Evofem Biosciences's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Evofem Biosciences's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-0.66/333.9520*333.9520
=-0.660

Current CPI (Jun. 2026) = 333.9520.

Evofem Biosciences Quarterly Data

Book Value per Share CPI Adj_Book
201609 11,205.755 241.428 15,500.208
201612 9,692.914 241.432 13,407.369
201703 7,348.946 243.801 10,066.387
201706 5,297.043 244.955 7,221.564
201709 3,944.500 246.819 5,337.003
201712 -1,564,509.887 246.524 -2,119,352.297
201803 -1,930.802 249.554 -2,583.790
201806 391.228 251.989 518.480
201809 -729.077 252.439 -964.497
201812 -1,692.971 251.233 -2,250.385
201903 -1,884.066 254.202 -2,475.148
201906 1,445.516 256.143 1,884.623
201909 964.724 256.759 1,254.762
201912 609.032 256.974 791.471
202003 38.564 258.115 49.895
202006 1,580.684 257.797 2,047.629
202009 927.577 260.280 1,190.127
202012 31.046 260.474 39.804
202103 -255.039 264.877 -321.548
202106 108.340 271.696 133.165
202109 -710.661 274.310 -865.177
202112 -1,203.631 278.802 -1,441.722
202203 -1,299.506 287.504 -1,509.449
202206 -341.517 296.311 -384.901
202209 -95.644 296.808 -107.613
202212 -72.909 296.797 -82.036
202303 -32.645 301.836 -36.118
202306 -22.052 305.109 -24.137
202309 -9.922 307.789 -10.765
202312 -3.324 306.746 -3.619
202403 -1.451 312.332 -1.551
202406 -0.837 314.175 -0.890
202409 -0.707 315.301 -0.749
202412 -0.629 315.605 -0.666
202503 -0.614 319.799 -0.641
202506 -0.587 322.561 -0.608
202509 -0.606 324.800 -0.623
202512 -0.587 324.054 -0.605
202603 -0.586 330.213 -0.593
202606 -0.660 333.952 -0.660

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Evofem Biosciences Business Description

Address 7770 Regents Road, Suite 113-618, San Diego, CA, USA, 92122
Evofem Biosciences Inc is a commercial-stage biopharmaceutical company committed to developing and commercializing products to address unmet needs in women's sexual and reproductive health. The company's product, Phexxi (lactic acid, citric acid, and potassium bitartrate), is a hormone-free, prescription vaginal gel approved in the United States for the prevention of pregnancy.